HemaSphere (Feb 2025)
Cytopenic overt primary myelofibrosis at presentation: Analysis of outcomes in the prospective, real‐world ERNEST‐2 registry
- Paola Guglielmelli,
- Arianna Ghirardi,
- Alessandra Carobbio,
- Arianna Masciulli,
- Lucrezia Morrone,
- Barbara Mora,
- Elisa Rumi,
- Ana Triguero,
- Maria C. Finazzi,
- Helna Pettersson,
- Valentina Boldrini,
- Daniele Vanni,
- Alessandro Rambaldi,
- Francesco Passamonti,
- Alberto Alvarez‐Larràn,
- Bjorn Andreasson,
- Alessandro M. Vannucchi,
- Tiziano Barbui
Affiliations
- Paola Guglielmelli
- Center of Research and Innovation of Myeloproliferative Neoplasms (CRIMM), Department of Experimental and Clinical Medicine, Azienda Ospedaliera Universitaria Careggi University of Florence Florence Italy
- Arianna Ghirardi
- FROM Research Foundation, Papa Giovanni XXIII Hospital Bergamo Italy
- Alessandra Carobbio
- FROM Research Foundation, Papa Giovanni XXIII Hospital Bergamo Italy
- Arianna Masciulli
- FROM Research Foundation, Papa Giovanni XXIII Hospital Bergamo Italy
- Lucrezia Morrone
- Center of Research and Innovation of Myeloproliferative Neoplasms (CRIMM), Department of Experimental and Clinical Medicine, Azienda Ospedaliera Universitaria Careggi University of Florence Florence Italy
- Barbara Mora
- Department of Hematology and Oncology, University of Milan Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milan Italy
- Elisa Rumi
- Division of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Department of Molecular Medicine University of Pavia Pavia Italy
- Ana Triguero
- Department of Hematology Hospital Clínic de Barcelona Barcelona Spain
- Maria C. Finazzi
- Department of Oncology‐Hematology University of Milan and Papa Giovanni XXIII Hospital Bergamo Italy
- Helna Pettersson
- Division of Hematology NU Hospital Group Uddevalla Sweden
- Valentina Boldrini
- Center of Research and Innovation of Myeloproliferative Neoplasms (CRIMM), Department of Experimental and Clinical Medicine, Azienda Ospedaliera Universitaria Careggi University of Florence Florence Italy
- Daniele Vanni
- Division of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Department of Molecular Medicine University of Pavia Pavia Italy
- Alessandro Rambaldi
- Department of Oncology‐Hematology University of Milan and Papa Giovanni XXIII Hospital Bergamo Italy
- Francesco Passamonti
- Department of Hematology and Oncology, University of Milan Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milan Italy
- Alberto Alvarez‐Larràn
- Department of Hematology Hospital Clínic de Barcelona Barcelona Spain
- Bjorn Andreasson
- Division of Hematology NU Hospital Group Uddevalla Sweden
- Alessandro M. Vannucchi
- Center of Research and Innovation of Myeloproliferative Neoplasms (CRIMM), Department of Experimental and Clinical Medicine, Azienda Ospedaliera Universitaria Careggi University of Florence Florence Italy
- Tiziano Barbui
- FROM Research Foundation, Papa Giovanni XXIII Hospital Bergamo Italy
- DOI
- https://doi.org/10.1002/hem3.70072
- Journal volume & issue
-
Vol. 9,
no. 2
pp. n/a – n/a
Abstract
No abstracts available.
